Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.
The American College of Rheumatology, in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis.
In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
A recent study discusses the findings of a study on patients with hematologic cancers who received convalescent plasma therapy following their diagnosis of COVID-19.
Due to sample size limitations, previous studies of DMARD use and COVID-19 outcomes have combined several different rheumatic diseases and medications, and investigated a single outcome- for example, the risk of hospitalization.
Researchers from the Federal University of Paraná, Brazil, looked into the seroconversion rate after vaccination with the CoronaVac. Using immunoassays, they measured the immunoglobulins (IgG) for anti-nucleocapsid protein (anti-N) antibodies and anti-spike-1 (anti-S1) protein antibodies.
Rheumatologists in Hong Kong joined hands to develop a set of consensus statements on COVID-19 vaccination for local adult patients with autoimmune rheumatic diseases. These timely statements would serve to be a guide for rheumatologists, other specialists, family physicians, specialty nurses, and the public regarding COVID-19 vaccination for patients with rheumatic diseases.
A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A.
Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.
Researchers at Children's Hospital of Philadelphia have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion of patients are either unresponsive or develop resistance towards R-CHOP—the standard treatment regimen.
A new study examines the associations between immunosuppressive disease-modifying therapies (DMTs) used in MS with adverse outcomes in an international cohort of patients with MS COVID-19.
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works.
The focus is increasingly moving towards vaccine roll-out as the world faces the real possibility of the second year of social and economic restrictions.
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
Primary central nervous system lymphoma (PCNSL) is a type of cancer that develops in the brain and or spinal cord.
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online during ASN Kidney Week 2020 Reimagined October 19-October 25.
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.
A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.